Neoleukin Therapeutics, Inc.

NASDAQ:NLTX

3.49 (USD) • At close December 18, 2023
Bedrijfsnaam Neoleukin Therapeutics, Inc.
Symbool NLTX
Munteenheid USD
Prijs 3.49
Beurswaarde 8,199,685
Dividendpercentage 0%
52-weken bereik 3.42 - 18.8
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Ms. Donna M. Cochener-Metcalfe J.D.
Website https://www.neoleukin.com

An error occurred while fetching data.

Over Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal

Vergelijkbare Aandelen

IN8bio, Inc. logo

IN8bio, Inc.

INAB

1.09 USD

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.

SPRO

1.36 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.65 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

2.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)